Generative AI delivers proteins that function to specification.

NVIDIA Partnership Highlight

Evozyne collaborated with NVIDIA to create and validate a new AI model that the pharmaceutical industry can use to design therapeutic proteins.

The novel approach exponentially increased the number and quality of synthetic protein designs for experimental testing. That capability translates to the ability to design new therapeutic targets for currently untreated diseases and greatly reduces development time for new therapies.

• Evozyne’s Protein Transformer Variational AutoEncoder (ProT-VAE) is built on NVIDIA BioNeMo
• Repeatable, functional results in less than 12 months
• Produced two novel proteins validated in experimental tests
  • A therapeutic biologic with 2.5-times better catalytic activity than wild type
  • An enzyme for biological CO2 capture with 61°C higher thermostability than the natural protein

Takeda and Evozyne are partnering to utilize innovative protein engineering technology to address treatment challenges in rare diseases, and to develop transformative therapy for patients.

• Delivered first result in 6 months.
• Designed a library of novel proteins with greatly improved functionality.
• Developing functional miniaturized genes that may aid in overcoming size constraints of viral vectors.